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INTRODUCTION
Corticotropin releasing factor (CRF), originally isolated from the mammalian hypothalamus, is a 41 amino acid peptide that regulates the activity of the hypothalamic-pituitary-adrenal axis by stimulating the secretion of hypophyseal corticotropin (ACTH) (Vale et al., 1981) . In addition to its major role in the regulation of the hypothalamic-pituitary-adrenal axis, CRF also functions as a neurotransmitter within the central nervous system and it is involved in the control of the gastrointestinal, behavioral, immune and reproductive systems (Gravanis and Margioris, 2005; Hillhouse and Grammatopoulos, 2006; Martinez et al., 2004; Venihaki and Majzoub, 2002) .
The CRF and its related peptides, including the 40-amino acid sauvagine, exert their actions by interacting with two types of CRF receptor, type 1 (CRF 1 ) and type 2 (CRF 2 ), which belong to subfamily B G-protein coupled receptors (GPCRs) (Chen et al., 1993; Lovenberg et al., 1995) .
CRF 1 , like the other GPCRs, consist of an amino-terminal extracellular region, a carboxylterminal intracellular tail and seven, mostly hydrophobic, membrane-spanning segments (TMs), connected by alternating intracellular (IL) and extracellular loops (EL) ( Fig. 1) (Grigoriadis et al., 2001) .
Previous structure-function studies using chimeric receptors, or mutants created by substituting, simultaneously, two or more wild type residues, have shown that the first, second and third extracellular loops of CRF 1 (EL1, EL2 and EL3, respectively) are involved in sauvagine and CRF binding (Liaw et al., 1997a; Liaw et al., 1997b; Sydow et al., 1999) .
However, these studies did not identify individual residues that are important for ligand/receptor interaction. In addition, the extracellular loops along with the membrane-spanning domains of CRF 1 have been suggested to interact with the amino-terminal portion of peptides belonging to the CRF family (Hoare et al., 2003; Nielsen et al., 2000) . This is in agreement with the important This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on November 4, 2016 molpharm.aspetjournals.org Downloaded from MOL #52423 5 functional role of the amino-terminal portion of CRF family peptides, as suggested in previous studies. Thus, substitution of most of the twenty amino-terminal residues of CRF by alanine, or by other amino acids, has been shown to produce significant decrease of peptide binding and biological potency (Beyermann et al., 1996; Kornreich et al., 1992; Rivier et al., 1993) .
Furthermore, deletion of the first nine or eleven amino-terminal residues from CRF and the corresponding eight or ten amino acids from sauvagine, resulted in a decrease in binding affinity and/or biological potency of peptides (Gulyas et al., 1995; Rivier et al., 2002; Rivier et al., 1984; Ruhmann et al., 1998) . However the amino acids of CRF 1 and the amino-terminal residues of sauvagine and CRF that interact with each other have so far been elusive.
Some information about the specific interactions emerged recently from a cross-linking study
showing that the amino-terminal Lys16 of sauvagine bound to CRF 1 is in close proximity to Lys257, which is located in the second extracellular loop of receptor (EL2) (Assil-Kishawi and Abou-Samra, 2002) ; but the residues involved in the interaction were not identified.
Based on the available information we reasoned that one or more residues located in the EL2 of CRF 1 possibly play a role in binding, most likely, to the amino-terminal portion of sauvagine and other CRF family peptides. This hypothesis considers as well the demonstrated role of EL2 of different subfamily B GPCRs in ligand binding and receptor function (Bergwitz et al., 1997; Vertongen et al., 2001) . To test this hypothesis, we determined the binding of sauvagine, CRF and analogs created by various truncations of the amino-terminal portions of these peptides, to wild type CRF 1 and EL2 mutants generated by alanine substitution (one at a time). Using these constructs, we find that Trp259 and Phe260 in the EL2 of CRF 1 play an important role in ligandreceptor interaction, interrelated with that of the amino-terminal portion of peptides of CRF family.
This article has not been copyedited and formatted. The final version may differ from this version. and Sauvagine(8-40), were synthesized by Fmoc/tBu methodology using "linker" (Rink Bernatowitz)-resin (2-chlorotrityl chloride/CLTR). L-amino acids were used with the appropriate protection groups at side chains as follows: Fmoc-Ile-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Pyr-OH. The coupling of each amino acid was achieved in the presence of N,N'diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazol (HOBt) in DMF solution. In each case the Fmoc protecting group was removed by treatment with piperidine solution (20% in DMF, 2 x 15 min). The Kaiser test and thin layer chromatography (TLC), n-butanol/acetic acid/water (4:1:1) (BAW) as eluent, verified the completeness of each coupling or Fmoc deprotection. Subsequently, the protected peptides-resin were treated with the splitting mixture DCM/TFE (7/3) for 2 h at room temperature in order to remove peptides from the resin followed by treatment with the solution of DCM/TFA/Ethanedithiol/Anisole/H 2 O (32/65/1/1/1), for 4 h at room temperature for complete removal of protecting groups. The resulting solutions were concentrated under vacuum to a small volume and the final free linear peptides after their precipitation (by adding diethyl ether) as a light-yellow amorphous solid, were filtered and dried in vacuo for 12 h (purity >60%). The final crude products were further purified with semipreparative RP-HPLC (column: Lichrosorb, RP-18, 250X10 mm). Separations were achieved with a stepped linear gradient of acetonitrile (AcN) (0.08%TFA) in water (0.08% TFA) for 50 min at a flow rate of 3 ml/min (gradient separation: 10%AcN to 70%AcN in 45 min). Peptides purity was assessed by analytical RP-HPLC (column: Nucleosil-120 C18, 250X4.0 mm, gradient This article has not been copyedited and formatted. The final version may differ from this version. Plasmids and site-directed mutagenesis. The cDNA sequence encoding the type 1 human corticotropin releasing factor receptor (CRF 1 ) was a gift from Dr. D. Grammatopoulos (Warwick University, UK). This cDNA was subcloned into the bicistronic expression vector pcin4 (Liapakis et al., 2000) , thereby creating the vector pcin4-CRF 1 . Alanine mutations were generated by the polymerase chain reaction (PCR)-mediated mutagenesis, using Pfu polymerase (Fermentas USA) and mutagenic oligonucleotides encoding the desired amino acid substitution, a gift from Dr. D. Grammatopoulos. The PCR-generated DNA fragments containing the alanine mutations were subcloned into the pcin4-CRF 1 plasmid and the mutations were confirmed by DNA sequencing. Alanine mutants are named as (wild-type residue)(residue number)(alanine), where the residues are given in the single-letter code.
MATERIALS AND METHODS
Synthesis of peptides. Sauvagine analogues, Sauvagine
Cell culture and transfection. Human embryonic kidney cells (HEK 293) were grown in DMEM/F12 (1:1) containing 3.15 g/L glucose and 10% bovine calf serum at 37 o C and 5% CO 2 .
Sixty mm dishes of HEK 293 cells at 80-90% confluence were transfected with 2-3 mg of wild type (WT) or mutant pcin4-CRF 1 using 9 µl of Lipofectamine (Invitrogen, USA) and 2 ml of OPTIMEM (Invitrogen, USA). To generate stably transfected pools of cells expressing the receptors five to twelve hours after transfection, the medium was replaced by DMEM/F12 (1:1) containing 3.15 g/L glucose, 10% bovine calf serum and 700 µg/ml of the antibiotic, Geneticin (Invitrogen, USA). The antibiotic was added to select a stably transfected pool of cells.
Harvesting cells and membrane preparation. Cells stably expressing WT or CRF 1 mutants were washed with phosphate-buffered saline (PBS) (4.3 mM Na 2 HPO 4 .7H 2 0, 1.4 mM KH 2 PO 4 , 137 mM NaCl, 2.7 mM KCl, pH 7.2-7.3 at R.T), briefly treated with PBS containing 2 mM This article has not been copyedited and formatted. The final version may differ from this version. 
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8 EDTA (PBS/EDTA), and then dissociated in PBS/EDTA. Cells suspensions were centrifuged at 1000 x g for 5 min at room temperature, and the pellets were homogenized in 1.5 ml of buffer H (20 mM HEPES, containing 10 mM MgCl 2 , 2 mM EGTA, 0.2 mg/ml bacitracin and 0.93 µg/ml aprotinin pH 7.2 at 4 o C) using a Janke & Kunkel IKA Ultra Turrax T25 homogenizer, at setting ~20, for 10-15 s, at 4 o C. The homogenates were centrifuged at 16000 x g, for 10 min, at 4 o C.
The membrane pellets were resuspended by homogenization, as described above, in 1 ml buffer B (buffer H containing 0.1% BSA, pH 7.2 at 20 o C). The membrane suspensions were diluted in buffer B and used for radioligand binding studies. competition binding was performed as described previously (Rominger et al., 1998) Inc., USA) or the non-peptidic analog, antalarmin (a gift from Dr. G. Chrousos, University of Athens). The mixtures were incubated at 20-21 °C for 120 min and then filtered using a Brandel cell harvester through Whatman 934AH glass fiber filters, presoaked for 1 hr in 0.3% polyethylenimine at 4 °C. The filters were washed 3 times with 0.5 ml of ice-cold PBS, pH 7.1 containing 0.01% Triton X-100. Filters were assessed for radioactivity in a gamma counter (LKB Wallac 1275 minigamma, 80% efficiency). The amount of membrane used was adjusted to insure that the specific binding was always equal to or less than 10% of the total concentration of This article has not been copyedited and formatted. The final version may differ from this version. cAMP Accumulation Assays. HEK 293 cells stably expressing WT or CRF 1 mutants were plated in 96-well cell culture plates (pretreated with poly-L-lysine, 0.1 mg/ml). After incubation overnight at 37 °C in 5% CO2, the cells were 95-100% confluent. The medium was removed, and 100 µl of assay buffer (25 mM HEPES, pH 7.4, 2 mM choline, 288 mM sucrose, 0.9 mM CaCl 2 , 0.5 mM MgCl 2 , and 1 mM 3-isobutyl-1-methylxanthine) was added. After 1 h incubation at 37 °C, more assay buffer without (basal levels) or with increasing concentrations of Tyr 0sauvagine was added to a total volume of 200 µl, and the incubation was continued for 20 min at 37 °C. At the end of the incubation the assay buffer was removed. The cells were placed on ice and lysed with 3% trichloroacetic acid. Lysates were incubated on ice for 30-60 min and stored at -20 °C. After 1-5 days, frozen lysates were thawed and centrifuged at 1800 x g for 10 min at 4°C, and the supernatants were neutralized with 2 N NaOH. Quantification of cAMP in the This article has not been copyedited and formatted. The final version may differ from this version. neutralized supernatants was performed using a competitive binding assay as described previously by Liapakis et al. (Liapakis et al., 2000) . Briefly, supernatants were transferred to polypropylene mini-tubes (20 µl /tube) containing buffer A (100 mM Tris-HCl, pH 7.4, 100 mM NaCl and 5 mM EDTA) with 1-1.5 nM [2,8-3 H] adenosine 3', 5'-cyclic phosphate (Amersham Pharmacia Biotech, USA). Subsequently, cAMP-binding protein (~100 mg of crude bovine adrenal cortex extract in 500 ml of buffer A) was added to each tube. After incubation on ice for 3 h, the mixtures were filtered through Whatman 934AH glass fiber filters as described for radioligand binding assays and using buffer C (120 mM NaCl, 10 mM Tris-HCl, pH 7.4 at 4 °C) as washing buffer. The amount of cAMP in each sample (one-tenth of a well) was determined by comparison with a standard curve of known concentrations of unlabeled cAMP (1-100 pmol/tube). EC 50 values were obtained by fitting the data to a one-site sigmoidal model using nonlinear regression analysis (GraphPad Prism 4.0). 
Determination of cell surface expression of CRF
RESULTS
In this study, we used alanine-scanning mutagenesis to investigate the role of the residues in the second extracellular loop (EL2) of CRF 1 in sauvagine binding and receptor function.
Specifically, we mutated to alanine the EL2 residues from Leu251 to Val266 (except for Cys258) (Fig. 1) , thus creating 15 different CRF 1 mutants. Cys258 was excluded because substitution by alanine abolished the binding of radiolabelled sauvagine (data not shown), in agreement with a previous study (Qi et al., 1997) , most likely due to its important role in receptor function by forming a disulfide bond with Cys188 in EL1 of CRF 1 (Qi et al., 1997) . Alanine scanning mutagenesis has been shown to yield important functional insight about proteins for which there is no complete structural information (Cunningham and Wells, 1989; Lu and Hulme, 1999; Ward et al., 1999) Effects of alanine mutations on the binding of CRF family peptides. Fig. 3 ).
Effects of alanine mutations on the binding of synthetic peptides and nonpeptide analogs.
To test whether W259A, F260A and W259A/F260A mutations alter the overall conformation of CRF 1 we determined their effects on binding of the peptide astressin and the non-peptide small molecule, antalarmin, which, as previously suggested, bind to different regions of CRF 1 (Hoare et al., 2003; Perrin et al., 1998) . In contrast to the native peptides CRF and sauvagine, the affinity of astressin was reduced by the W259A, F260A and W259A/F260A mutations only 2.5-, 2.5and 3.5-fold respectively (Table 1, Fig. 4 ). Similarly antalarmin affinity was not significantly decreased (1.5-fold) by W259A and F260A mutations (Fig. 4) , whereas the simultaneous mutation of Trp259 and Phe260 to alanine did not change the binding affinity of this small nonpeptide molecule (Fig. 4) .
Previous studies have suggested that the extracellular loops of CRF 1 likely interact with the amino-terminal portion of peptides belonging to the CRF family (Hoare et al., 2003; Nielsen et interaction with the amino-terminal portion of CRF and sauvagine we determined the effects of W259A, F260A and W259A/F260A mutations on binding affinities of several analogs of CRF and sauvagine produced by their truncation at the amino-terminal portion. As mentioned above, W259A, F260A and W259A/F260A mutations did not significantly alter the binding of astressin, which is a truncated analogue of CRF, lacking the first 11 amino-terminal residues of CRF (Table 1) . Similar to astressin, W259A, F260A and W259A/F260A mutations did not significantly affect the affinity of sauvagine(11-40), which is the truncated analog of sauvagine corresponding to CRF analog astressin (Table 1 , Fig. 5 ).
To further identify which of the first 10 and 11 amino-terminal residues of sauvagine and CRF, respectively, play a role in peptide interaction with Trp259 and Phe260, we determined the effects of W259A, F260A and W259A/F260A mutations on the binding affinities of sauvagine(8-40) and alpha-helical CRF(9-41). Alpha-helical CRF(9-41) is a truncated analog of CRF lacking the first eight amino-terminal residues of CRF (Rivier et al., 1984) and sauvagine(8-40) is the corresponding truncated analog of sauvagine (Table 1) . These analogs, therefore, have three amino-terminal residues more than astressin and sauvagine(11-40).
Removing the side chains of Trp259 and Phe260, by mutating them to alanine, individually (W259A and F260A) or simultaneously (W259A/F260A), largely decreased the binding affinity of alpha-helical CRF(9-41) (> 6.5-fold) ( 5 ).
Activation of adenylyl cyclase. The functional properties of CRF 1 before and after alanine mutations of EL2 residues were assessed in cAMP accumulation experiments. We determined the ability of Tyr 0 -sauvagine to stimulate cAMP accumulation in HEK 293 cells stably expressing WT CRF 1 or mutant receptors, and found the effects of alanine mutations on the potency of Tyr 0 -sauvagine to be similar with those on its binding affinity. Alanine mutation of the residues from Leu251 to Lys257 and from Gly261 to Val266 in the EL2 of CRF 1 did not significantly affect the potency of Tyr 0 -sauvagine (Fig. 6) . In contrast, W259A and F260A mutations decreased the potency of Tyr 0 -sauvagine to stimulate cAMP accumulation, 65.5 and 56.5-fold, respectively ( Fig.6 and 7) . In agreement with the effects of the simultaneous mutation of Trp259 and Phe260 to alanine on the binding affinity of Tyr 0 -sauvagine, 259A/260A mutation decreased more than additively (161.5-fold) its potency to stimulate cAMP accumulation ( Fig. 6 and 7). In contrast to potency, the maximal stimulation of cAMP accumulation by Tyr 0sauvagine was much less affected by W259A and F260A mutations, whereas it was not reduced by the W259A/F260A mutation (Fig. 7) . The effect of W259A, F260A and W259A/F260A mutations on Tyr 0 -sauvagine potency and maximal ability to stimulate cAMP accumulation was not due to a mutation-associated decrease in cell surface expression of CRF 1 because these mutations did not decrease the number of cell surface receptors as determined in flow cytometry experiments, using a CRF 1 selective antibody (Fig. 8) .
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DISCUSSION
Alanine substitution of most of the residues in EL2 of CRF 1 (Leu251 to Lys257, and Gly261
to Val266) did not significantly change the binding affinity for sauvagine, and its potency to stimulate cAMP accumulation. Alanine substitution of a receptor residue that interacts with a ligand has been suggested to disrupt the interaction without affecting the receptor's overall conformation (Cunningham and Wells, 1989) . Thus, we conclude that the EL2 residues Leu251-Lys257 and Gly261-Val266 do not interact with sauvagine. Surprisingly, among these residues, Lys257 has been shown to lie in close proximity to CRF 1 -bound sauvagine (Assil-Kishawi and Abou-Samra, 2002) . This, in conjunction with the results of our study, suggests that Lys257 is possibly located in the interface between sauvagine and receptor, without however contributing significantly to the overall binding energy. This is similar to the conclusion reached in (Clackson and Wells, 1995) based on the X-ray structure of human growth hormone in complex with its receptor, and a thorough mutational analysis of both of these proteins; Clackson and Wells suggested that only a small fraction of the contact residues in the ligand/receptor complex contribute significantly to the overall binding energy.
However, we find for two residues in EL2, Trp259 and Phe260, that alanine substitution reduced both binding affinity and functional potency of sauvagine. In contrast, these mutations did not significantly affect the affinities of ligands considered to interact with receptor regions other than EL2 (Hoare et al., 2003; Perrin et al., 1998) , i.e., astressin and antalarmin. These results suggest that Trp259 and Phe260 play an important, most likely direct, role in sauvagine binding, without significantly altering the overall conformation of the CRF 1 protein. Notably, Trp259 and Phe260 are located only two amino acids away from Lys257, which has been shown to be positioned near CRF 1 -bound sauvagine (Assil-Kishawi and Abou-Samra, 2002) . Furthermore, previous studies have suggested that only few of the interactions between receptor and ligand, may be important for binding and these are predominantly interactions between hydrophobic residues, such as typtophan and phenylalanine (Clackson and Wells, 1995; Young et al., 1994) . The results of our study are in agreement with previous studies on different GPCRs, which have shown that the EL2 plays an important role in ligand binding (Audoly and Breyer, 1997; Bergwitz et al., 1997; Holtmann et al., 1996; Moro et al., 1999; Runge et al., 2003; Shi and Javitch, 2004) .
Similar to our findings for sauvagine, the same two residues mutated to alanine reduced CRF affinity as well, suggesting a role for Trp259 and Phe260 in the binding of various peptides belonging to CRF family, possibly being common contact sites for them.
All the effects we measured for these two mutant constructs (W259A and F260A) on the affinities of amino-terminal truncated peptides (astressin, a CRF analog lacking the first eleven amino-terminal residues (Gulyas et al., 1995) ; We note that the F260A mutation decreased the affinity of the truncated CRF analog, alpha helical CRF (9-41), without however having any effect on the affinity of the corresponding to alpha helical CRF (9-41), truncated analog of sauvagine, sauvagine(8-40). A possible explanation for this discrepancy could be that these truncated analogs of CRF and sauvagine are likely to bind in different ways to CRF1. The different affinities between the alpha helical CRF (9-41), the three residues shorter CRF-truncated analog astressin and the full-length CRF could also be attributed to a possible different mode of their binding to CRF 1 . Previous studies have shown that the high affinity binding of CRF (full agonist), is due to two sets of interactions (Hoare et al., 2003; Nielsen et al., 2000) ; a first one between the amino-terminal portion of CRF and the J-domain (membrane-spanning domains and extracellular loops) of receptor and a second one between the carboxyl-terminal portion of peptide and the N-domain (amino-terminal extracellular region) of CRF 1 . Deletion of the first 11 amino-terminal residues of CRF (thus creating the antagonist astressin) likely abolished the first set of interactions (or the most important ones for CRF function) and repositioned the peptide into the receptor such as to conserve its high affinity binding but losing its ability to activate the CRF 1 . In contrast, deletion of some, but not all, of the first 11 amino-terminal residues of CRF (thus creating the partial agonist, alpha helical CRF (9-41)) likely abolished part of the first set of interactions with the remaining ones to position the truncated peptide into CRF 1 in such a way (possibly different than that of CRF) as to bind with lower affinity to receptor and having partial agonist properties. The concept that different peptides belonging to CRF family bind differentially to CRF 1 has also been suggested in a previous study, in which the pharmacological properties of different peptides were differentially affected by several mutations of receptor (Assil et al., 2001) .
This article has not been copyedited and formatted. The final version may differ from this version. The larger than additive effect of simultaneous substitution of Trp259 and Phe260 with alanine on the affinity of sauvagine and CRF suggests a combined role in binding for these adjacently positioned residues. This finding is similar to the observation of the super-additive effect of simultaneous alanine substitution for Ser203 and Ser204 in the beta2 adrenergic receptor on epinephrine binding (Liapakis et al., 2000) . These two serines have been shown to participate in a network of hydrogen-bond interactions with the meta-OH of catecholamines, as well as with other receptor residues (Liapakis et al., 2000) .
Conclusively, this study, for first time revealed that Trp259 and Phe260 in the EL2 of CRF 1 play an important role in ligand-receptor interaction, interrelated with that of the amino-terminal portion of peptides of CRF family. In addition, the interplay between the amino-terminal portion of peptides and Trp259 and Phe260 seems to be critical for CRF 1 activation and the subsequent appearance of a biological effect (truncation of the amino-terminal portion of peptides resulted in the creation of antagonists, such as astressin, which are insensitive to alanine mutations of Trp259 and Phe260). This conclusion substantiates the key role of EL2 of CRF 1 in the translation of agonist binding to receptor activation, a role that is likely related both to its position in the receptor structure, near the key (for receptor function) TMs 4, 5 and 6, and to its own conformational properties that we are now exploring.
This article has not been copyedited and formatted. The final version may differ from this version. given in Table 1 . This article has not been copyedited and formatted. The final version may differ from this version. Peptide binding to wild type (WT) CRF 1 and mutants. Competition binding studies were performed on membrane preparations from HEK 293 cells stably expressing wild type (WT) CRF 1 or mutant receptors, as described in "Materials and Methods". The -logIC 50 values were obtained by fitting the data to a one-site competition model by nonlinear regression. The -logK i values were determined from the -logIC 50 values, according to the method of Cheng and Prusoff (Cheng and Prusoff, 1973) . The -logK D values (italics) were taken from Fig. 2 . The mean ± S.E. values are from 3-8 independent experiments. Values in parentheses are K i or K D values of the mutants for each agonist divided by the K i or K D value of WT, respectively. These values represent the decrease (↓) in the affinity after the modification of CRF 1 . 
-log K D or -log K i Amino terminal amino residues of peptides
